Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSun Yat-sen University
About this trial
Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
Eligibility criteria
Qualifiers
Pathologically confirmed, initially treated, surgically resectable head and neck squamous cell carcinoma.
Clinical stage III to IVB (AJCC 8th edition), except HPV-positive oropharyngeal cancer
Following multidisciplinary discussions involving otolaryngologists and radiation oncologists, the assessment concluded that the tumor is resectable or marginally resectable and suitable for preoperative SBRT
Karnofsky Performance Status score ≥ 70
Disqualifiers
Patients previously treated with head and neck surgery were excluded from diagnostic biopsies of primary and regional lymph nodes
Previous chemotherapy for any reason, or radiotherapy in the head and neck area, or molecular targeted drug therapy; Previously received anti-PD-1, anti-PD-L1, anti-PD-L2 and other drugs or drugs acting on another irritating or co-inhibitory T cell receptor (such as CTLA-4, OX 40, CD137) treatment, or cell biotherapy
Pregnant or lactating women
Have had or co-had other malignancies
Trial design
Treatments tested in this trial
- Tislelizumab
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov